中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.028 seconds)

    Methods for treatment of conditions associated with lactosylceramide
    1.
    发明授权
    Methods for treatment of conditions associated with lactosylceramide 有权
    用于治疗与乳糖神经酰胺相关的病症的方法

    公开(公告)号：US06228889B1

    公开(公告)日：2001-05-08

    申请号：US09340341

    申请日：1999-06-25

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: A61K3116

    CPC classification number: A61K31/40 ,  A61K31/16 ,  A61K31/445 ,  A61K31/535

    Abstract: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration for a mammal, particularly a human, of a therapeutically effective amount of a compound that inhibits UDPGal:GlcCer&bgr;1−>4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.

    Abstract translation: 本发明包括治疗和预防与乳糖神经酰胺相关的疾病，手术后疾病和细菌感染的方法。 所述方法通常提供给予哺乳动物特别是人类治疗有效量的抑制UDPGal：GlcCerβ1→4半乳糖神经酰胺（GalT-2）的化合物。 还提供了用于检测具有调节GalT-2的治疗能力的化合物的体外和体内测定。

    PECAM-1 GENOTYPE
    3.
    发明申请
    PECAM-1 GENOTYPE 审中-公开
    PECAM-1基因组

    公开(公告)号：US20090208934A1

    公开(公告)日：2009-08-20

    申请号：US11794871

    申请日：2006-01-05

    Applicant: Subroto Chatterjee ,  Heiming Wei

    Inventor： Subroto Chatterjee ,  Heiming Wei

    IPC: C12Q1/68 ,  C40B40/08 ,  C12N5/08

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: The invention relates to methods of identifying inter-patient differences in genotype of PECAM-1 to diagnose and assess risk of arterial disease. It further relates to methods of identifying therapeutics agents for to treat coronary arterial disease, and to methods for determining and exploiting such differences to improve medical outcomes.

    Abstract translation: 本发明涉及鉴定PECAM-1基因型患者间差异以诊断和评估动脉疾病风险的方法。 它还涉及鉴定用于治疗冠状动脉疾病的治疗剂的方法，以及用于确定和利用这些差异以改善医学结果的方法。

    Receptor-based assays for pathogens
    4.
    发明授权
    Receptor-based assays for pathogens 失效
    基于受体的病原体测定

    公开(公告)号：US06528272B2

    公开(公告)日：2003-03-04

    申请号：US09019435

    申请日：1998-02-05

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: G01N3353

    CPC classification number: G01N33/545 ,  G01N33/54306 ,  G01N33/569 ,  G01N33/56911 ,  G01N33/56916 ,  G01N33/56938 ,  G01N33/56972 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57426 ,  G01N33/92 ,  G01N2405/10 ,  Y02A50/52 ,  Y10S435/975 ,  Y10S436/808

    Abstract: A rapid, simple, and inexpensive sandwich enzyme-linked receptor based immunodot assay detects pathogens or pathogenic products in test samples using receptors for a characteristic component of the pathogen. This assay is widely applicable because it is highly specific, it does not require special equipment, and the results can be obtained within a few hours with the naked eye. Since the lipid-based receptors have a long-shelf life, they can be easily stored and used for a long time.

    Abstract translation: 基于快速，简单且廉价的夹心酶联免疫斑点免疫测定法利用受体作为病原体的特征成分检测试验样品中的病原体或致病物。 该测定法广泛适用，因为它是高度特异性的，不需要特殊设备，并且可以在肉眼几小时内获得结果。 由于基于脂质的受体具有长寿命，因此它们可以容易地长时间储存​​和使用。

    NOVEL APOC-I ISOFORMS AND THEIR USE AS BIOMARKERS AND RISK FACTORS OF ATHEROSCLEROTIC DISEASE
    9.
    发明申请
    NOVEL APOC-I ISOFORMS AND THEIR USE AS BIOMARKERS AND RISK FACTORS OF ATHEROSCLEROTIC DISEASE 审中-公开
    新型APOC-I ISOFORMS及其作为生物标志物和ATHEROSCLEROTIC DISEASE的风险因素

    公开(公告)号：US20140193846A1

    公开(公告)日：2014-07-10

    申请号：US14112670

    申请日：2011-12-23

    Applicant: Ronald D. Macfarlane ,  Catherine J. McNeal ,  Subroto Chatterjee

    Inventor： Ronald D. Macfarlane ,  Catherine J. McNeal ,  Subroto Chatterjee

    IPC: G01N33/92

    CPC classification number: G01N33/92 ,  C07K14/775 ,  G01N2800/324 ,  G01N2800/50

    Abstract: Novel isoforms of apolipoprotein C-I (apoC-I), namely apolipoprotein C-I1 (apoC-I1) and apolipoprotein C-I1′ (apoC-I1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein C-I (SEQ ID NO:6) and native apolipoprotein C-I′ (SEQ ID NO:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.

    Abstract translation: 载脂蛋白C1（apoC-I），即载脂蛋白C-I1（apoC-I1）和载脂蛋白C-I1'（apoC-I1'）的新型同工型，其分子量比天然载脂蛋白CI大约为90道尔顿 （SEQ ID NO：6）和天然载脂蛋白C1'（SEQ ID NO：7）显示为用于诊断动脉粥样硬化疾病的生物标志物以及具有发展动脉粥样硬化疾病风险增加的受试者的危险因素。

Patent Agency Ranking